Skip to main content

Advertisement

Table 2 Clinical efficacy data at final analysis on 43 patients

From: Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Number of cycles (median - range) 5 [1 - 21]
Treatment response (n - %)
  CR 1/43 – 2.3%
  PR 7/43 - 16.3%
  SD 17/43 - 39.5%
  PD 18/43 - 41.9%
  Clinical benefit 25/43 - 58.1%
  ORR 8/43 - 18.6%
TTP (median - range) 5 [2 - 21] months
OS (median - range) 9 [3 - 29] months
Percentage of alive patients (n - %)
  year 1 16/43 - 37.2%
  year 2 4/43 - 9.3%
  1. CR = complete response; PR = partial response; SD = stable disease; PD = disease progression; ORR = overall response rate; TTP = time to progression; OS = overall survival.